Table 2.

The CAMARADES quality items

Authors & Year	➀	➁	➂	➃	➄	➅	➆	➇	➈	➉	Quality score
Zhang et al. 2006 [17]	√	√	√	√			√	√		√	7
Zhou et al. 2012 [13]	√	√			√		√	√	√	√	7
Zhang et al. 2006 [27]	√	√	√				√	√		√	6
Xing et al. 2006 [28]	√	√	√				√	√		√	6
Xie et al. 2005 [29]	√						√	√		√	4
Chu et al. 2005 [30]	√	√	√				√	√		√	6
Huang et al. 2008 [31]	√	√	√					√		√	5
Huang et al. 2008 [32]	√	√	√					√		√	5
Liu et al. 2012 [33]	√	√	√				√	√		√	6
Chu et al. 2004 [34]	√	√					√	√		√	5
Ye et al. 2003 [35]	√		√				√	√		√	5
Ye et al. 2005 [36]	√	√	√				√	√		√	6
Wang et al. 2007 [12]	√	√					√	√		√	6
Luo et al. 2009 [15]	√	√			√		√	√	√	√	7
Hou et al. 2011 [40]	√	√			√		√	√	√	√	7
Luo et al. 2010 [37]	√	√	√					√		√	5
Zhao et al. 2004 [38]	√	√			√		√	√	√	√	7
Luo et al. 2012 [39]	√	√					√	√		√	5

(1) peer reviewed publication; (2) presence of randomization of subjects into treatment groups; (3) assessment of dose–response relationship; (4) blinded assessment of behavioral outcome; (5) monitoring of physiological parameters such as body temperature; (6) calculation of necessary sample size to achieve sufficient power; (7) statement of compliance with animal welfare regulations; (8) avoidance of anesthetic agents with marked intrinsic neuroprotective properties (e.g., ketamine); (9) statement of potential conflict of interests; (10) use of a suitable animal model